News

Virginia Innovation Partnership Corporation Introduces New Name of CIT GAP Funds: Virginia Venture Partners

Virginia Innovation Partnership Corporation (VIPC) has announced a new name for CIT GAP Funds: Virginia Venture Partners. The family of funds places equity investments in Virginia’s high-growth based technology, life science, and cleantech companies at the earliest developmental stages. This new name reflects the investment program’s renewed commitment to the Commonwealth and enduring partnerships with Virginia’s high-tech entrepreneurs.

“What we want to do is capitalize on the strengths that we have and build on those,” said Bob Stolle, President and CEO, VIPC. “Connecting innovators with opportunities is our business as we continue to work to provide the leadership necessary for funding, infrastructure and policy initiatives that support success for Virginia’s innovators, entrepreneurs, startups, market development and investment strategies. The renaming of the CIT GAP Funds to the Virginia Venture Partners reflects our new vision and mission as VIPC which is a critical part of the process.”

The mission of Virginia Venture Partners remains the same: invest in Virginia’s leading technology, clean tech and life science start-ups that have a high potential for achieving rapid growth and generating significant economic return for entrepreneurs, co-investors and the Commonwealth of Virginia. Additional goals of Virginia Venture Partners include increasing support for traditionally underrepresented entrepreneurs, enabling portfolio company creation of new jobs, and providing new outreach events and resources for startups.

“Since the fund’s inception in 2005, we have invested in over 260 portfolio companies and have achieved significant return on investment and socio-economic impact for the Commonwealth of Virginia. Our new name, Virginia Venture Partners, is an exciting transition that highlights the noteworthy state of innovation in our region,” said Tom Weithman, VIPC Chief Investment Officer and Managing Director of Virginia Venture Partners. “Our investment team remains as committed as ever to providing balanced support for Virginia’s high-growth early stage companies, including financial investment, access to our ever expanding network and trusted advisory services to portfolio companies.”

Virginia Venture Partners will retain the names of its core investment funds:

  • Flagship seed funds: GAP Tech, GAP Life Sciences, and GAP Clean Energy
  • Pre-Seed funds: Virginia Founders Fund, focused on women founders and founders of color; and Virginia Partners Fund, focused on investing in companies in traditionally underserved geographies and working with key partners throughout the Virginia ecosystem

According to its 2020 Impact Report, Virginia Venture Partners, as CIT GAP Funds, has catalyzed over $1.1B of investment from more than 1,000 third-party investors and has been acknowledged by CBI Insight as Virginia’s most active investor for seven successive years.

Read more on Globe Newswire.

 

Recent News

10/23/2024

Advancing Pharmaceutical Manufacturing in Central Virginia: The Success of the GO Virginia Grant

Activation Capital is proud to announce the successful closeout of a pivotal GO Virginia grant, addressing the urgent need to secure access to and reduce the costs of essential medicines. This grant laid the foundation for Central Virginia’s growth as a hub for advanced pharmaceutical manufacturing (APM) by leveraging the region’s strengths in advanced manufacturing,

10/22/2024

Caretaker Medical Awarded the Grand Prize in NIH RADx Tech for Maternal Health Challenge

Caretaker Medical, a digital health company focused on developing hemodynamic monitoring devices, today announced that it has been awarded the $525,000 grand prize in the US National Institutes of Health (NIH) Rapid Acceleration of Diagnostics Technology for Maternal Health Challenge. The award recognizes Caretaker’s wireless, wearable wrist device, VitalStream, that can be used to monitor

10/22/2024

Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces the further expansion of its on-going Netherton Syndrome (NS) clinical studies to include two additional international sites in the United Kingdom (UK). These sites, Great Ormond Street Hospital and St. Thomas’ Hospital,